2018
Impact of Cost Display on Ordering Patterns for Hospital Laboratory and Imaging Services
Silvestri MT, Xu X, Long T, Bongiovanni T, Bernstein SL, Chaudhry SI, Silvestri JI, Stolar M, Greene EJ, Dziura JD, Gross CP, Krumholz HM. Impact of Cost Display on Ordering Patterns for Hospital Laboratory and Imaging Services. Journal Of General Internal Medicine 2018, 33: 1268-1275. PMID: 29845468, PMCID: PMC6082197, DOI: 10.1007/s11606-018-4495-6.Peer-Reviewed Original ResearchConceptsDecreased oddsImaging ordersHealth care servicesBehalf of patientsKey ResultsDuringMain MeasuresOutcomesParticipantsAll patientsHospital encountersImaging testsObservation encountersCare servicesHealth servicesMedicare fee scheduleHealth systemImaging costsDecreased numberHospital laboratoriesLab ordersStudy periodHospital labPatients
2017
Outcomes after observation stays among older adult Medicare beneficiaries in the USA: retrospective cohort study
Dharmarajan K, Qin L, Bierlein M, Choi JES, Lin Z, Desai NR, Spatz ES, Krumholz HM, Venkatesh AK. Outcomes after observation stays among older adult Medicare beneficiaries in the USA: retrospective cohort study. The BMJ 2017, 357: j2616. PMID: 28634181, PMCID: PMC5476173, DOI: 10.1136/bmj.j2616.Peer-Reviewed Original ResearchCopy Fees and Limitation of Patients’ Access to Their Own Medical Records
Jaspers AW, Cox JL, Krumholz HM. Copy Fees and Limitation of Patients’ Access to Their Own Medical Records. JAMA Internal Medicine 2017, 177: 457-458. PMID: 28135350, DOI: 10.1001/jamainternmed.2016.8560.Peer-Reviewed Original Research
2012
Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies
Downing NS, Aminawung JA, Shah ND, Braunstein JB, Krumholz HM, Ross JS. Regulatory Review of Novel Therapeutics — Comparison of Three Regulatory Agencies. New England Journal Of Medicine 2012, 366: 2284-2293. PMID: 22591257, PMCID: PMC3504361, DOI: 10.1056/nejmsa1200223.Peer-Reviewed Original ResearchConceptsNovel therapeutic agentsEuropean Medicines AgencyHealth CanadaTherapeutic agentsNew therapeutic agentsMedian lengthTherapeutic comparisonsDrug AdministrationMedicines AgencyNew drug applicationsPrescription Drug User Fee ActNovel therapeuticsDrug applicationFDAUnique agentUnited StatesTotal review timeFirst reviewRegulatory agenciesReview timeDaysAgentsReviewRegulatory reviewVast majority